{"nctId":"NCT01881113","briefTitle":"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","startDateStruct":{"date":"2013-06"},"conditions":["Allergic Conjunctivitis"],"count":101,"armGroups":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL","interventionNames":["Drug: AC-170 0.24%"]},{"label":"AC-170 0%","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AC-170 0%"]}],"interventions":[{"name":"AC-170 0.24%","otherNames":[]},{"name":"AC-170 0%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* positive bilateral conjunctival allergen challenge (CAC) reaction\n\nExclusion Criteria:\n\n* known contraindications or sensitivities to the study medication or its components\n* any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters\n* use of disallowed medication during the period indicated prior to the enrollment or during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"0.933"},{"groupId":"OG001","value":"2.86","spread":"0.748"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"0.947"},{"groupId":"OG001","value":"2.94","spread":"0.712"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"1.026"},{"groupId":"OG001","value":"2.66","spread":"0.809"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"1.006"},{"groupId":"OG001","value":"2.54","spread":"0.943"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.002"},{"groupId":"OG001","value":"2.51","spread":"0.875"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"1.006"},{"groupId":"OG001","value":"2.23","spread":"0.956"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":"0.702"},{"groupId":"OG001","value":"2.39","spread":"0.619"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"0.639"},{"groupId":"OG001","value":"2.38","spread":"0.602"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"0.701"},{"groupId":"OG001","value":"2.40","spread":"0.639"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"0.713"},{"groupId":"OG001","value":"2.38","spread":"0.653"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"0.608"},{"groupId":"OG001","value":"2.37","spread":"0.661"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"0.646"},{"groupId":"OG001","value":"2.41","spread":"0.651"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"0.794"},{"groupId":"OG001","value":"2.15","spread":"0.689"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":"0.753"},{"groupId":"OG001","value":"2.05","spread":"0.777"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"0.801"},{"groupId":"OG001","value":"2.19","spread":"0.659"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.62","spread":"0.945"},{"groupId":"OG001","value":"2.29","spread":"0.803"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":"0.793"},{"groupId":"OG001","value":"2.34","spread":"0.780"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"0.779"},{"groupId":"OG001","value":"2.36","spread":"0.784"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"0.662"},{"groupId":"OG001","value":"2.29","spread":"0.567"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":"0.663"},{"groupId":"OG001","value":"2.27","spread":"0.605"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":"0.689"},{"groupId":"OG001","value":"2.30","spread":"0.640"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"0.798"},{"groupId":"OG001","value":"2.31","spread":"0.575"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":"0.645"},{"groupId":"OG001","value":"2.32","spread":"0.582"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"0.655"},{"groupId":"OG001","value":"2.36","spread":"0.604"}]}]}]},{"type":"SECONDARY","title":"Chemosis at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.540"},{"groupId":"OG001","value":"0.96","spread":"0.666"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.627"},{"groupId":"OG001","value":"1.28","spread":"0.773"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"0.753"},{"groupId":"OG001","value":"1.27","spread":"0.785"}]}]}]},{"type":"SECONDARY","title":"Chemosis at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.387"},{"groupId":"OG001","value":"0.58","spread":"0.519"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"0.585"},{"groupId":"OG001","value":"0.75","spread":"0.671"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.626"},{"groupId":"OG001","value":"0.85","spread":"0.702"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.70"},{"groupId":"OG001","value":"1.4","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.71"},{"groupId":"OG001","value":"1.4","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.91"},{"groupId":"OG001","value":"1.4","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.67"},{"groupId":"OG001","value":"1.2","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.76"},{"groupId":"OG001","value":"1.3","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.70"},{"groupId":"OG001","value":"1.2","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Tearing at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.67"},{"groupId":"OG001","value":"1.2","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.90"},{"groupId":"OG001","value":"1.2","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.98"},{"groupId":"OG001","value":"1.0","spread":"1.01"}]}]}]},{"type":"SECONDARY","title":"Tearing at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.61"},{"groupId":"OG001","value":"1.1","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.62"},{"groupId":"OG001","value":"1.1","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.65"},{"groupId":"OG001","value":"1.0","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Rhinorrhea at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.85"},{"groupId":"OG001","value":"1.1","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.89"},{"groupId":"OG001","value":"1.3","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.01"},{"groupId":"OG001","value":"1.3","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Rhinorrhea at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.70"},{"groupId":"OG001","value":"1.3","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.89"},{"groupId":"OG001","value":"1.3","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.78"},{"groupId":"OG001","value":"1.1","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Nasal Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.79"},{"groupId":"OG001","value":"0.9","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.01"},{"groupId":"OG001","value":"1.0","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.00"},{"groupId":"OG001","value":"0.9","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Nasal Pruritus at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.76"},{"groupId":"OG001","value":"0.8","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.05"},{"groupId":"OG001","value":"0.8","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.87"},{"groupId":"OG001","value":"0.9","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Ear or Palate Pruritus at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.73"},{"groupId":"OG001","value":"1.2","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.00"},{"groupId":"OG001","value":"1.5","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.14"},{"groupId":"OG001","value":"1.6","spread":"1.27"}]}]}]},{"type":"SECONDARY","title":"Ear or Palate Pruritus at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.74"},{"groupId":"OG001","value":"0.8","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.05"},{"groupId":"OG001","value":"1.3","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.06"},{"groupId":"OG001","value":"1.3","spread":"1.24"}]}]}]},{"type":"SECONDARY","title":"Nasal Congestion at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.68"},{"groupId":"OG001","value":"1.0","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.85"},{"groupId":"OG001","value":"1.4","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.08"},{"groupId":"OG001","value":"1.3","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Nasal Congestion at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.73"},{"groupId":"OG001","value":"1.1","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.86"},{"groupId":"OG001","value":"1.3","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.85"},{"groupId":"OG001","value":"1.3","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Nasal Symptom at Duration of Action (8 Hours + 30 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Nasal Symptom at Onset of Action (15 Minutes Post-Dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null},{"groupId":"OG001","value":"86.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability of Study Medication at Visit 3A","description":"Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.02"},{"groupId":"OG001","value":"0.8","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.33"},{"groupId":"OG001","value":"1.1","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"2.14"},{"groupId":"OG001","value":"1.1","spread":"1.13"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Visual acuity reduced","Epistaxis","Rhinitis allergic","Dermatitis contact","Road traffic accident"]}}}